NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Zero patients with idh mutation enrolling in this (DCVax-l) trial would be unusual, because it was not in the exclusion criteria. One thing I’d mention, is although a percentage of idh mutation patients (which typically make up only 10% of GBM patients) live longer, it does not likely have anything to do with TMZ, and may be in spite of it.

I assume your thought that there may be less IDH mutation than 10% in the trial is because, in the past, outside the trial, Dr. Liau was not a proponent of utilizing DC therapy on idh mutation patients in her compassionate care cases at UCLA and would refer them to other trials, because she believed idh mutation was almost akin to something other than GBM altogether. (Ahead of her time, but the neuro-oncology world is coming ‘round to this.)

I’d also assume you are thinking lower number of patients with IDH mutations in this trial because a substantial number are typically below 18 years of age.